Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Enzyme Inhib Med Chem ; 33(1): 607-614, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29532688

ABSTRACT

Xanthohumol (XN), a prenylated chalcone unique to hops (Humulus lupulus) and two derived prenylflavanones, isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) gained increasing attention as potential anti-diabetic and cancer preventive compounds. Two enzymes of the aldo-keto reductase (AKR) superfamily are notable pharmacological targets in cancer therapy (AKR1B10) and in the treatment of diabetic complications (AKR1B1). Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 µM, 0.34 µM, 0.71 µM) and of human AKR1B10 (Ki = 20.11 µM, 2.25 µM, 1.95 µM). The activity of the related enzyme AKR1A1 was left unaffected by all three compounds. This is the first time these three substances have been tested on AKRs. The results of this study may provide a basis for further quantitative structure?activity relationship models and promising scaffolds for future anti-diabetic or carcinopreventive drugs.


Subject(s)
Aldo-Keto Reductases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Flavanones/pharmacology , Flavonoids/pharmacology , Humulus/chemistry , Propiophenones/pharmacology , Xanthones/pharmacology , Aldo-Keto Reductases/metabolism , Binding Sites/drug effects , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemistry , Flavanones/chemistry , Flavonoids/chemistry , Humans , Molecular Structure , Propiophenones/chemistry , Structure-Activity Relationship , Xanthones/chemistry
2.
J Enzyme Inhib Med Chem ; 32(1): 1152-1158, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28856935

ABSTRACT

Aldose reductase (AR) is an enzyme devoted to cell detoxification and at the same time is strongly involved in the aetiology of secondary diabetic complications and the amplification of inflammatory phenomena. AR is subjected to intense inhibition studies and dimethyl sulfoxide (DMSO) is often present in the assay mixture to keep the inhibitors in solution. DMSO was revealed to act as a weak but well detectable AR differential inhibitor, acting as a competitive inhibitor of the L-idose reduction, as a mixed type of non-competitive inhibitor of HNE reduction and being inactive towards 3-glutathionyl-4-hydroxynonanal transformation. A kinetic model of DMSO action with respect to differently acting inhibitors was analysed. Three AR inhibitors, namely the flavonoids neohesperidin dihydrochalcone, rutin and phloretin, were used to evaluate the effects of DMSO on the inhibition studies on the reduction of L-idose and HNE.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Dimethyl Sulfoxide/pharmacology , Enzyme Inhibitors/pharmacology , Aldehyde Reductase/isolation & purification , Aldehyde Reductase/metabolism , Dimethyl Sulfoxide/chemical synthesis , Dimethyl Sulfoxide/chemistry , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Humans , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Solvents/chemical synthesis , Solvents/chemistry , Solvents/pharmacology , Structure-Activity Relationship
3.
Chem Biol Interact ; 276: 155-159, 2017 Oct 01.
Article in English | MEDLINE | ID: mdl-28159579

ABSTRACT

The hyperactivity of aldose reductase (AR) on glucose in diabetic conditions or on glutathionyl-hydroxynonenal in oxidative stress conditions, the source of cell damage and inflammation, appear to be balanced by the detoxifying action exerted by the enzyme. This detoxification acts on cytotoxic hydrophobic aldehydes deriving from membrane peroxidative processes. This may contribute to the failure in drug development for humans to favorably intervene in diabetic complications and inflammation, despite the specificity and high efficiency of several available aldose reductase inhibitors. This paper presents additional features to a previously proposed approach, on inhibiting the enzyme through molecules able to preferentially inhibit the enzyme depending on the substrate the enzyme is working on. These differential inhibitors (ARDIs) should act on glucose reduction catalyzed by AR without little or no effect on the reduction of alkenals or alkanals. The reasons why AR may be an eligible enzyme for differential inhibition are considered. These mainly refer to the evidence that, although AR is an unspecific enzyme that recognizes different substrates such as aldoses and hydrophobic aldehydes, it nevertheless displays a certain degree of specificity among substrates of the same class. After screening on edible vegetables, indications of the presence of molecules potentially acting as ARDIs are reported.


Subject(s)
Aldehyde Reductase/metabolism , Enzyme Inhibitors/metabolism , Vegetables/chemistry , Aldehyde Reductase/antagonists & inhibitors , Aldehyde Reductase/genetics , Enzyme Inhibitors/chemistry , Glucose/metabolism , Humans , Phaseolus/chemistry , Phaseolus/metabolism , Plant Extracts/chemistry , Plant Extracts/metabolism , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Substrate Specificity , Vegetables/metabolism
4.
Food Nutr Res ; 60: 31792, 2016.
Article in English | MEDLINE | ID: mdl-27415159

ABSTRACT

BACKGROUND: The Zolfino bean is a variety of Phaseolus vulgaris, which is cultivated in a limited area of Tuscany, Italy, and is widely appreciated for its flavor and culinary uses. OBJECTIVES: A yellow Zolfino landrace cultivated in the Leccio-Reggello area was characterized and compared with three other varieties of Phaseolus vulgaris (i.e. the Borlotto, Cannellino, and Corona beans) in terms of its general features and potential as an antioxidant/anti-inflammatory agent. DESIGN: The length, width, thickness, equatorial section surface, weight, volume, and seed coat section were measured in all the beans. The seed surface area was also estimated by an original empirical method. The ability of the different beans to interfere with the enzymes of the polyol pathway (that is, aldose reductase (AR) and sorbitol dehydrogenase) was tested using the supernatant after soaking the beans at room temperature and after thermal treatment, which simulated the bean-cooking process in a controlled fashion. RESULTS: Concerning the general features, Zolfino was comparable with other beans, except Corona, in terms of surface-volume ratio, which possesses the lowest tegument thickness. Moreover, Zolfino appears the most effective in inhibiting AR activity. The inhibitory ability is unaffected by thermal treatment and appears to be associated with compound(s) present in the coat of the bean. CONCLUSIONS: The ability of Zolfino to inhibit AR, thus reducing the flux of glucose through the polyol pathway, highlights the features of Zolfino as a functional food, potentially useful in treating the dysfunctions linked to the hyperactivity of AR, such as diabetic complications or inflammatory responses.

SELECTION OF CITATIONS
SEARCH DETAIL
...